Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New strategy developed to diagnose melanoma

01.04.2009
A UCSF research team has developed a technique to distinguish benign moles from malignant melanomas by measuring differences in levels of genetic markers.

Standard microscopic examinations of biopsied tissue can be ambiguous and somewhat subjective, the researchers say, and supplementing standard practice with the new technique is expected to help clarify difficult-to-diagnose cases.

In a large study of previously diagnosed cases, the new technique distinguished between benign, mole-like skin lesions and melanomas with a success rate higher than 90 percent. It also succeeded with most of the previously misdiagnosed cases, which were among the most difficult to distinguish.

This is the first large-scale study to demonstrate both the high diagnostic accuracy and practicality of a multi-biomarker approach to melanoma diagnosis, said Mohammed Kashani-Sabet, MD, professor of dermatology at UCSF and director of the Melanoma Center at the UCSF Helen Diller Family Comprehensive Cancer Center.

Kashani-Sabet is lead author on a paper reporting the new finding in the Proceedings of the National Academy of Sciences, which is scheduled for online publication the week of March 30, 2009. The paper also will appear in a future print issue of PNAS.

Melanoma is the deadliest form of skin cancer. It can spread to almost any organ of the body and is difficult to treat in its advanced stages. Progress in survival rates has been made principally through earlier diagnosis. The genomics-based approach combined with current diagnostic practice can aid earlier detection and contribute to more accurate assessment, report the UCSF scientists who developed the diagnostic tool.

The molecular diagnosis strategy is now being developed for clinical use by a diagnostics company.

To develop the diagnostic tool, the researchers first used a microarray – a "gene chip" -- to identify about 1,000 human genes that were present at different levels in malignant melanomas compared to benign moles. They narrowed their study down to five genes that all showed higher levels of activity in melanomas than in moles and could be studied with standard antibody techniques.

Focusing on the proteins produced by the five genes, they stained the proteins with antibodies to assess the level of gene expression in mole and melanoma tissues. The new diagnostic technique distinguished moles from melanomas by differences in both the level and the pattern of activity of the five proteins.

To develop and test the diagnostic technique, the researchers examined levels of the five biomarkers in 693 previously diagnosed tissue samples. To ensure that the diagnosis based on tissue examination had been correct, all samples were reviewed by the study's pathologist. They analyzed the samples with the new procedure and found that the increased protein production by the melanomas compared with the moles was statistically significant, and thus a reliable diagnostic indicator. Unexpectedly, the proteins also showed different patterns of activity in the two types of tissue, yielding a second, even more discriminating diagnostic indicator.

"We hoped for clear diagnostic differences in the intensity of gene expression," Kashani-Sabet said. "We found what we had hoped for, but then we got a bonus. The pattern of protein activity from the top to the bottom of the tissue was strikingly different between the benign and the malignant tissue, providing an additional trait valuable for diagnosis."

Although some of the genes and their proteins were stronger indicators than others, the research team found that the combination of all five achieved the highest diagnostic accuracy. The multi-biomarker diagnostic correctly diagnosed 95 percent of the benign moles -- a measure known as specificity. The accuracy rate was 91 percent for diagnosing malignant melanomas – the sensitivity rate. In addition, the strategy correctly diagnosed 75 percent of the most difficult cases, which had previously been misdiagnosed. The technique also accurately diagnosed other difficult-to-diagnose moles, known as dysplastic and Spitz nevi.

"We have a test that can help patients and help clinicians who treat melanoma," said Kashani-Sabet. "With this added diagnostic tool we can shed light on lesions that are difficult to classify and diagnose."

Co-authors on the paper and collaborators in the research, all at UCSF, are Javier Rangel, MD, resident in dermatology; Mehdi Nosrati, BS, staff research assistant; and Sima Torabian, MD, a former post-doctoral research fellow in the Kashani-Sabet lab.

Also, Jeff Simko, MD, associate professor of clinical pathology; Chris Haqq, MD, PhD, assistant adjunct professor of urology; James Miller, PhD, statistical consultant; Richard Sagebiel, MD, professor of dermatology and pathology; Dan Moore, PhD, statistical consultant; and David Jablons, MD, professor of surgery.

A patent has been filed by UCSF covering the use of these five genetic markers in melanoma diagnosis. The patent has been licensed to Melanoma Diagnostics, based in Fremont, Calif. Lead author Kashani-Sabet owns stock in this company. Co-author Miller has an ownership interest in MDMS, a software company in Arizona that provided the software to generate diagnostic algorithms.

The research was supported by the Auerback Melanoma Research Fund, the Herschel and Diana Zackheim Endowment Fund, the American Cancer Society and the National Institutes of Health.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Susan Cohen | EurekAlert!
Further information:
http://www.ucsf.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>